EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

KLF13 restrains Dll4‐muscular Notch2 axis to improve the muscle atrophy

Shu Yang iD, Lijiao Xiong, Guangyan Yang, Jiaqing Xiang, Lixing Li, Lin Kang, Zhen Liang

Journal of Cachexia, Sarcopenia and Muscle · 2024

DOI: 10.1002/jcsm.13538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Shu Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen, China. Hauptthemen laut MEDLINE: Disease Models, Animal, Muscular Atrophy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Sustainable Development Science and Technology Special Project, China, Key Program Topics of Shenzhen Basic Research, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Muscle atrophy can cause muscle dysfunction and weakness. Krüppel‐like factor 13 (KLF13), a central regulator of cellular energy metabolism, is highly expressed in skeletal muscles and implicated in the pathogenesis of several diseases. This study investigated the role of KLF13 in muscle atrophy, which could be a novel therapeutic target.

Methods

The effects of gene knockdown and pharmacological targeting of KLF13 on skeletal muscle atrophy were investigated using cell‐based and animal models. Clofoctol, an antibiotic and KLF13 agonist, was also investigated as a candidate for repurposing. The mechanisms related to skeletal muscle atrophy were assessed by measuring the expression levels and activation statuses of key regulatory pathways and validated using gene knockdown and RNA sequencing.

Results

In a dexamethasone‐induced muscle atrophy mouse model, the KLF13 knockout group had decreased muscle strength (N) (1.77 ± 0.10 vs. 1.48 ± 0.16, P < 0.01), muscle weight (%) [gastrocnemius (Gas): 76.0 ± 5.69 vs. 60.7 ± 7.23, P < 0.001; tibialis anterior (TA): 75.8 ± 6.21 vs. 67.5 ± 5.01, P < 0.05], and exhaustive running distance (m) (495.5 ± 64.8 vs. 315.5 ± 60.9, P < 0.05) compared with the control group. KLF13 overexpression preserved muscle mass (Gas: 100 ± 6.38 vs. 120 ± 14.4, P < 0.01) and the exhaustive running distance (423.8 ± 59.04 vs. 530.2 ± 77.45, P < 0.05) in an in vivo diabetes‐induced skeletal muscle atrophy model. Clofoctol treatment protected against dexamethasone‐induced muscle atrophy. Myotubes treated with dexamethasone, an atrophy‐inducing glucocorticoid, were aggravated by KLF13 knockout, but anti‐atrophic effects were achieved by inducing KLF13 overexpression. We performed a transcriptome analysis and luciferase reporter assays to further explore this mechanism, finding that delta‐like 4 ( Dll4 ) was a novel target gene of KLF13. The KLF13 transcript repressed Dll4, inhibiting the Dll4‐Notch2 axis and preventing muscle atrophy. Dexamethasone inhibited KLF13 expression by inhibiting myogenic differentiation 1 (i.e., MYOD1)‐mediated KLF13 transcriptional activation and promoting F‐Box and WD repeat domain containing 7 (i.e., FBXW7)‐mediated KLF13 ubiquitination.

Conclusions

This study sheds new light on the mechanisms underlying skeletal muscle atrophy and potential drug targets. KLF13 regulates muscle atrophy and is a potential therapeutic target. Clofoctol is an attractive compound for repurposing studies to treat skeletal muscle atrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease Models, AnimalMuscular AtrophyAnimalsHumansMaleMiceKruppel-Like Transcription FactorsMice, KnockoutMuscle, SkeletalSignal TransductionReceptor, Notch2Calcium-Binding ProteinsAdaptor Proteins, Signal TransducingRepressor ProteinsCell Cycle Proteins

Stichwörter der Autor:innen

ClofoctolDLL4KLF13NotchSarcopenia

Substanzen

Kruppel-Like Transcription FactorsNOTCH2 protein, humanReceptor, Notch2Notch2 protein, mouseDLL4 protein, humanCalcium-Binding ProteinsAdaptor Proteins, Signal TransducingDLL4 protein, mouseKLF13 protein, humanRepressor Proteins

Autor:innen und Institutionen

  • Department of Geriatrics, The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen, China.
  • Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Center for Geriatrics, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, China.
  • The Biobank of National Innovation Center for Advanced Medical Devices, Shenzhen People's Hospital, Shenzhen, China.

ORCID-Profile: Shu Yang

Förderung

  • National Natural Science Foundation of China
  • Shenzhen Sustainable Development Science and Technology Special Project, China
  • Key Program Topics of Shenzhen Basic Research, China

Zitieren

APA

Yang, S., Xiong, L., Yang, G., Xiang, J., Li, L., Kang, L., & Liang, Z. (2024). KLF13 restrains Dll4‐muscular Notch2 axis to improve the muscle atrophy. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13538

Vancouver

Yang S, Xiong L, Yang G, Xiang J, Li L, Kang L, et al. KLF13 restrains Dll4‐muscular Notch2 axis to improve the muscle atrophy. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13538

BibTeX
@article{Yang2024,
  author = {Yang, Shu and Xiong, Lijiao and Yang, Guangyan and Xiang, Jiaqing and Li, Lixing and Kang, Lin and Liang, Zhen},
  title = {KLF13 restrains Dll4‐muscular Notch2 axis to improve the muscle atrophy},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2024},
  doi = {10.1002/jcsm.13538}
}
Kostenlos starten →